Targeting β-catenin and PD-L1 simultaneously by a racemic supramolecular peptide for the potent immunotherapy of hepatocellular carcinoma

Objective: The low clinical utility of immune checkpoint inhibitors (ICIs) against PD-1 or PD-L1 has recently been associated with the activation of the Wnt/β-catenin signaling pathway in hepatocellular carcinoma (HCC), which promotes tumor immune escape and resistance to anti-PD-1/PD-L1 therapy. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zhengjun, Li, Xiao, Yang, Guang, Wang, Jingmei, Li, Baohua, Huang, Yinong, Yan, Jin, Tao, Kaishan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10283047/
https://www.ncbi.nlm.nih.gov/pubmed/37351175
http://dx.doi.org/10.7150/thno.83377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10283047/
https://www.ncbi.nlm.nih.gov/pubmed/37351175
http://dx.doi.org/10.7150/thno.83377

Ejemplares similares